Nanjing Xiangyuan Biomedical Technology

Nanjing Xiangyuan Biomedical Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-unmet-need areas within oncology and autoimmune diseases, leveraging its internal R&D capabilities to build a robust pipeline. Its lead candidate, XY0206, is a multi-target kinase inhibitor targeting FLT3 and AXL, currently being evaluated in clinical trials for the treatment of acute myeloid leukemia. Additionally, the company is advancing XY03-518, a selective CDK4/6 inhibitor for breast cancer, alongside several pre-clinical programs targeting RET and MET kinases.